Table 1.
Changes in CYP metabolic ratios during chemotherapy for breast cancer.
| Enzyme | Phenotyping | n | Before chemo phenotype ratio* | After chemo phenotype ratio* | After chemo/before chemo ratio (90% CI) | p** |
|---|---|---|---|---|---|---|
| CYP2C9 | losartan/ E-3174 | 8 | 1.54 | 1.74 | 1.79 (0.79–2.78) | 0.55 |
| CYP2C19 | omeprazole/5-hydroxyomeprazole | 9 | 2.27 | 3.00 | 1.02 (0.78–1.26) | 0.82 |
| CYP2D6 | dextromethorphan/dextrorphan | 8 | 0.65 | 0.68 | 1.26 (0.64–1.87) | 1.00 |
| CYP3A4 | midazolam/α-hydroxymidazolam | 9 | 2.18 | 2.29 | 1.08 (0.81–1.35) | 0.91 |
CI, confidence interval.
*Mean ratios.
**Statistical analysis was performed using Wilcoxon matched-pairs signed rank testing, and significance was determined as p < 0.05.